Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
APTOAptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
APTO• Safety Review Committee endorses escalation to 160 mg TUS dosing; no dose-limiting toxicities to date
Nasdaq Surges 1%; US Construction Spending Rises In February
APTOWhy Aptose Biosciences (APTO) Stock Is Down Over 40%
APTOAptose Biosciences shares are trading lower by 53.7% during Tuesday's session. The company announced it is going to delist from the Nasdaq.
Dow Dips Over 400 Points; ISM Manufacturing PMI Falls In March
APTOHC Wainwright & Co. Maintains Buy on Aptose Biosciences, Raises Price Target to $6
APTOTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
APTOWhy Is Penny Stock Aptose Biosciences Trading Higher On Thursday?
APTOAptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.
Aptose Announces Cohort Safety Review Committee Monitoring Phase 1/2 TUSCANY Trial Of TUS+VEN+AZA Unanimously Approved Escalating From 40 mg TUS To 80 mg TUS
APTOAptose Biosciences Plans To Consolidate Common Shares On The Basis Of 1- For-30 Reverse Share Split
APTOUS Stocks Likely To Open Higher Amid Ukraine Peace Talk Hopes As Russian, American Officials Meet
APTOU.S. stock futures rose on Tuesday following a mixed close on Friday after the Presidents' Day holiday on Monday.
Aptose Enters $25M Committed Equity Facility And Enters At-the-Market Distributions
APTOCORRECTION: HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $2 Price Target (Firm Name Change From RBC To HC Wainwright & Co.)
APTORBC Capital Reiterates Buy on Aptose Biosciences, Maintains $2 Price Target
APTOAptose Biosciences Reported Promising Early Safety And Response Results From Newly Diagnosed AML Patients In The Phase 1/2 TUSCANY Trial
APTOAptose Reports Early Safety And Response Results In Phase 1/2 TUSCANY Trial Of Tuspetinib In Combination With Standard Of Care Dosing Of Venetoclax And Azacitidine; Says TUS+VEN+AZA Triplet Achieved Cycle 1 Complete Remission In TP53-Mutated/CK AML
APTOHC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $2 Price Target
APTOAptose Announces First AML Patients Dosed With Tuspetinib Triplet Frontline Therapy In Tuscany Trial
APTOAptose Granted Extension To Evidence Compliance For Continued Nasdaq Listing
APTOHC Wainwright & Co. Maintains Buy on Aptose Biosciences, Lowers Price Target to $2
APTOAptose Biosciences Announced Initiation Of The TUSCANY Study, Tuspetinib In Combination Therapy With Azacitidine And Venetoclax As A Frontline Triplet Combination Therapy For Patients Newly Diagnosed With Acute Myeloid Leukemia
APTOCanaccord Genuity Maintains Buy on Aptose Biosciences, Lowers Price Target to $6
APTOFDA Grants Fast Track designation To Aptose Biosciences for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
APTOAptose Biosciences Inc. (NASDAQ: APTO) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation.
Aptose Receives Fast Track Designation For HM43239 In Relapsed/Refractory AML Patients And FLT3 Mutation
APTOAptose Biosciences Announces Luxeptinib Preclinical Data Extend Potential Applications From Oncology To Inflammation
APTO